Research programme: neurodegenerative diseases therapeutics - Cognition Therapeutics

Drug Profile

Research programme: neurodegenerative diseases therapeutics - Cognition Therapeutics

Alternative Names: amyloid beta-protein inhibitors - Cognition Therapeutics; CT 0093; CT 0109; CT 013441; CT 013461

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Cognition Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Progesterone receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 29 Sep 2016 Preclinical trials in Parkinson's disease in USA (unspecified route)
  • 15 Mar 2016 Biomarkers information updated
  • 21 May 2014 Cognition Therapeutics receives funding from the National Institute on Aging for development of small molecule soluble amyloid beta receptor antagonists in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top